International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
Successful treatment with rezafungin after micafungin for relapsing Rasamsonia argillacea species complex pneumonia in a patient with bronchiectasis: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bes-Berlandier Hugo, Coron Noémie, Pottier Heloise, Manni Sabrina, Mortier Coline, Bouchara Jean Philippe, Barrera Coralie, Bellanger-Clerget Anne-Pauline, Millon Laurence, Parize Perrine, Lanternier Fanny, Lortholary Olivier, Bermudez Julien, Cassir Nadim, Coiffard Benjamin
Аннотация
Rasamsonia argillacea species complex are emerging opportunistic molds increasingly reported in patients with chronic lung disease. We describe a 69-year-old woman with bronchiectasis who developed relapsing R. aegroticola pneumonia. After transient improvement with micafungin, relapse occurred, and antifungal therapy was switched to rezafungin, a novel echinocandin with a prolonged half-life and front-loaded pharmacokinetics. A total of 3 months of treatment led to clinical and radiological improvement, with sustained stability 6 months after therapy completion. This case illustrates the pathogenic role of R. argillacea species complex in non-immunocompromised hosts and suggests rezafungin as a promising therapeutic option for echinocandin-susceptible, azole-resistant Rasamsonia infections.